S-1: Oragenics Seeks Up to $5 Million in Public Offering to Advance Concussion Treatment

Oragenics, Inc. announces a public offering of common stock and pre-funded warrants to raise up to $5 million for the development of its ONP-002 concussion treatment and for general corporate purposes.

Summary

• Oragenics, Inc. is undertaking a public offering to sell up to 2,403,846 shares of common stock and pre-funded warrants to raise approximately $5 million.
• The assumed offering price is $2.08 per share, based on the closing price on August 12, 2024, but the actual price will be determined with the placement agent.
• The company intends to use the net proceeds to fund clinical trials for its ONP-002 concussion treatment, related research and development, and for general working capital.
• The offering will terminate no later than September 16, 2024, unless terminated earlier by the company.
• Dawson James Securities, Inc. is acting as the placement agent for the offering and will receive a cash fee equal to 7% of the gross proceeds raised.
• The company's stock is listed on NYSE American under the symbol OGEN.
• The company has a history of losses and will need to raise additional capital in the future.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company may not be able to satisfy the continued listing standards of the NYSE American and may be delisted from the NYSE American.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive aspects such as the ongoing development of ONP-002 and the engagement of experienced medical advisors, the company's financial situation, including its history of losses and the auditor's doubt about its ability to continue as a going concern, weighs heavily on the overall sentiment.

Positives

• The company has completed Phase 1 clinical trials for ONP-002, showing it is safe and well-tolerated.
• The company has developed a new proprietary formulation for the ONP-002 neurosteroid.
• The company's candidate for treating concussion successfully completed a study that indicates the ONP-002 drug does not cause cardiotoxicity.
• The company successfully completed a study that indicates the ONP-002 drug does not cause DNA damage and genotoxicity in an animal model.
• The company has engaged experienced medical advisors to oversee the upcoming Phase II clinical trial for treating concussion.

Negatives

• The company has incurred significant losses since its inception and has limited financial resources.
• The company does not generate any revenues and will need to raise additional capital in the future.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company may not be able to satisfy the continued listing standards of the NYSE American and may be delisted from the NYSE American.
• The company has limited neurology-specific research, development, manufacturing, testing, regulatory, commercialization, sales, distribution, and marketing experience, and we may need to invest significant financial and management resources to establish these capabilities.
• None of the company's product candidates have been approved for sale and if the company is unable to successfully develop its product candidates, it may not be able to continue as a going concern.

Risks

• The company may not be able to secure additional funding.
• The company's product candidates, if approved, will face significant competition; many of our competitors have significantly greater resources and experience.
• The market opportunities for the company's neurology product candidates may be smaller than the company believes them to be and the company cannot assure you that the market and consumers will accept its products or product candidates.
• If the company's manufacturers and suppliers fail to meet its requirements and the requirements of regulatory authorities, its research and development may be materially adversely affected.
• The company relies on the significant experience and specialized expertise of its senior management and scientific team and the loss of any of its key personnel or its inability to successfully hire their successors could harm its business.
• If any of the company's product candidates are shown to be ineffective or harmful in humans, the company will be unable to generate revenues from these product candidates.
• The company might not be successful at acquiring, investing in or integrating businesses, entering into joint ventures or divesting businesses.
• The company's concussion and neurology related research and development efforts are to a large extent dependent upon its intellectual property and biologicals materials licenses.
• The company may not be able to protect its intellectual property and if the company is unable to protect its trademarks or other intellectual property from infringement, its business prospects may be harmed.
• The company may be subject to claims challenging the inventorship of its patents and other intellectual property rights.
• If the company is sued for infringing intellectual property rights of third parties, it will be costly and time-consuming and an unfavorable outcome in that litigation could have a material adverse effect on its business.
• The company's success will depend on its ability to partner or sub-license its product candidates.
• Security breaches and other disruptions to the company's information technology systems or those of the vendors on whom it relies on could compromise its information and expose it to liability, reputational damage, or other costs.
• The company's product candidates are subject to substantial government regulation and will be subject to ongoing and continued regulatory review and the company may also be subject to healthcare laws, regulation and enforcement.
• The company may be unable to obtain regulatory approval for its product candidates under applicable regulatory requirements.
• Delays or difficulties in the enrollment of patients in clinical trials may result in additional costs and delays.
• The company's product candidates may cause serious or undesirable side effects.
• The company's employees, independent contractors, principal investigators, consultants, vendors and CROs may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
• Even if the company's current product candidates or any future product candidates obtain regulatory approval, they may fail to achieve the broad degree of health care payers, physician and patient adoption and use necessary for commercial success.
• The issuance of additional equity securities by the company in the future will result in dilution and the conversion of its outstanding preferred stock will result in significant dilution.
• The company's Series A and Series B preferred stock, if not converted into common stock, has a distribution and liquidation preference senior to its common stock in liquidation which could negatively affect the value of its common stock and impair its ability to raise additional capital.
• Certain provisions of the company's articles of incorporation, bylaws, executive employment agreements and stock option plan may prevent a change of control of its company that a shareholder may consider favorable.
• The price and volume of the company's common stock has been volatile and fluctuates substantially.
• The requirements of being a public company may strain the company's resources, divert management's attention and affect its ability to attract and retain qualified members for its Board of Directors.
• If the company fails to maintain an effective system of internal controls, it may not be able to accurately report its financial results or prevent fraud.

Future Outlook

The company intends to use the net proceeds from this offering, along with its existing cash and cash equivalents, to fund its ongoing ONP-2 concussion clinical trials, along with other related research and development activities, as well as for working capital and other general corporate purposes. The net proceeds from this offering, together with our cash, will not be sufficient for us to fund our ONP-002 product candidate through regulatory approval, and we will need to raise additional capital to complete the development and commercialization of our ONP-002 product candidate.

Management Comments

• The acquisition is expected to build on our expertise in intranasal platforms and expand our portfolio into more areas of unmet medical needs.
• We believe the nasal cavity provides access for our novel neurosteroid formulation to enter the brain in minutes.
• We believe that our recent work has increased the final dose levels significantly while also providing for improved intranasal drug delivery and adhesion and, thus, longer absorption times.
• We further believe we have successfully completed an improved proprietary formulation of the ONP-002 drug that should significantly increase the bioavailability of the intranasal drug formulation.

Industry Context

The global market for concussion treatment was valued at $6.9 billion in 2020 and is forecast to reach $8.9 billion by 2027, according to Grandview Research, indicating a significant market opportunity for effective concussion treatments.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• Without specific data on clinical trial outcomes, drug efficacy, or market penetration strategies, it's difficult to benchmark Oragenics against competitors like BioDirection, Inc. (developing TBI blood tests) or companies with established concussion management protocols such as ImPACT Applications, Inc.
• A more detailed analysis would require comparing Oragenics' ONP-002 to other neuroprotective agents in development, assessing its delivery method against existing intranasal drug delivery technologies (e.g., those used by Impel NeuroPharma), and evaluating its cost-effectiveness relative to standard concussion care practices.

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• The company's ability to continue as a going concern is dependent on the success of its clinical trials and its ability to raise additional capital.
• Employees' job security is tied to the company's financial stability and the success of its product development efforts.
• Patients with concussions could benefit from the successful development of ONP-002.

Next Steps

• The company anticipates preparing for Phase 2 clinical trials to further evaluate the ONP-002 drugs safety and efficacy.
• The company plans to apply for an Investigational New Drug application with the FDA and conduct a Phase II trial in the United States.
• The company anticipates a Phase 2 clinical trial will be performed administering the ONP-002 drug intranasally in concussed patients 2x a day for up to fourteen days.
• The Phase 2a feasibility study is expected to be performed in Australia with a target initiation date in the second or third quarter of 2024 to be followed closely by a Phase 2b proof of concept study in the US.

Key Dates

Keywords

ONP-002, concussion, mTBI, public offering, pre-funded warrants, clinical trials, neurology, Oragenics, stock, financing